LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in consultation with The Nasdaq Stock Market LLC (Nasdaq), it has submitted its plan to Nasdaq to regain compliance with the minimum bid price requirement and the minimum stockholders’ equity requirement for continued listing on The... Read More

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of action, producing IL-12 and key anti-cancer immune cytokines in the tumor-microenvironment post-treatment Company currently advancing Phase 3 pivotal trial of IMNN-001, with first two sites initiated LAWRENCEVILLE, N.J., June... Read More

Clinical Data Highlight PlaCCine’s Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines IMUNON Seeks Strategic Partner for PlaCCine ® to Advance Novel Technology and Fund Core Pipeline with Non-Dilutive Capital LAWRENCEVILLE, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and... Read More

LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of Imunon, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, June 12, 2025, at 11:30 a.m. ET. Pre-register for Imunon’s virtual presentation at... Read More

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, including those with BRAC1 and BRCA2 mutations LAWRENCEVILLE, N.J., June 03, 2025... Read More

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June 02, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN ) Dear Valued Shareholders, A Year of Breakthroughs: IMUNON Has Never Been Stronger As I mark my first year as President and CEO of IMUNON, I am thrilled... Read More

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today closed on the previously announced sale of an aggregate of 7,222,223 shares of its common stock (or... Read More

Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading peer-reviewed journal Gynecologic Oncology details IMNN-001’s outstanding safety and efficacy across multiple analyses and subgroups Treatment with IMNN-001 could represent new promise for estimated 40,000 women newly diagnosed with... Read More

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- I MUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of... Read More

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of care chemotherapy plus PARP inhibitors achieved nearly 12-month increase in PFS compared to standard of care; median OS in IMNN-001 treatment arm not yet reached after more than five years Phase 2 OVATION 2... Read More

LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (SEC) of the Company’s Registration Statement on Form S-1 (No. 333-286403), as amended, originally filed on April 4, 2025 (Registration Statement), as the... Read More

Company’s PlaCCine ® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential applications in COVID-19 and other infectious diseases with epidemic implications LAWRENCEVILLE, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company focused on developing non-viral... Read More

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development with its... Read More

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, with new IMNN-001 data to be highlighted in oral presentation at 2025 ASCO Annual Meeting LAWRENCEVILLE, N.J., May 08,... Read More

Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that data from the company’s Phase 1/2 OVATION 2 trial evaluating intraperitoneal IMNN-001 in combination with neoadjuvant and... Read More

LAWRENCEVILLE, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, May 12, 2025 to discuss financial results for the first quarter ended March 31, 2025 and provide an update on its clinical development program with IMNN-001, a DNA-based... Read More

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 following alignment on protocol with FDA LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that... Read More

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivotal trial of DNA-mediated IL-12 therapeutic Company to hold conference call on Tuesday, March 25, 2025, at 2:00 p.m. ET LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage... Read More

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 2025 Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated... Read More

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine ® technology IMNN-101 induced 2- to 4-fold increase in neutralizing antibody (NAb) titers from baseline through Week 4 IMNN-101 continues to show an acceptable safety profile LAWRENCEVILLE, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company focused on... Read More

LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will report full year 2024 financial results before the opening of the U.S. financial markets on Thursday, February 27, 2025. The Company will host a conference call that same day beginning at 11:00 a.m. ET to discuss the... Read More

Data reinforce dose-dependent mechanism with IMNN-001 100mg/m 2 dose associated with 20% increase in IL-12 levels compared to 79mg/m 2 dose Results from OVATION 2 Study continue to validate TheraPlas ® technology, demonstrating DNA-mediated production of key anti-cancer immune cytokines following treatment IMNN-001 continues to show favorable safety profile, with no reports of serious immune-related adverse events... Read More

Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective... Read More

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable future manufacturing capability On track to initiate Phase 3 pivotal trial of IMNN-001 in first quarter of 2025 LAWRENCEVILLE, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in... Read More

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian cancer Median OS increased from 11 to 13 months in IMNN-001 treatment group based on latest data analysis No change in IMNN-001 favorable safety profile including no reports of serious immune-related adverse events IMUNON remains on... Read More

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint Final Protocol submission on track for December, supporting initiation of Phase 3 registrational trial in Q1 2025 LAWRENCEVILLE, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late-stage development with... Read More

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was generally well tolerated, with no reports of cytokine release syndrome or any other serious immune related adverse events Company plans to initiate Phase 3 pivotal trial of IMNN-001 in Q1 2025 LAWRENCEVILLE, N.J., Nov. 07, 2024... Read More

Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three and nine months ended September 30, 2024. The Company also provided an update on its clinical development of IMNN-001 including progress toward commencing a Phase 3... Read More

LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 7, 2024 to discuss financial results for the third quarter ended September 30, 2024 and provide an update on its clinical... Read More

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance Company also announces FDA End-of-Phase 2 in-person meeting to discuss Phase 3 trial of IMNN-001 Phase 3 trial is expected to begin in Q1 2025 LAWRENCEVILLE, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the... Read More

LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options to purchase a total of 60,000 shares of the Company’s common stock to one individual hired by Imunon... Read More

September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline LAWRENCEVILLE, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, will hold its first Ovarian Cancer R&D Day on September 18, 2024... Read More

September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline LAWRENCEVILLE, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, will hold its first Ovarian Cancer R&D Day on September 18, 2024... Read More

R&D Discussion in New York City to Review IL-12’s Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts LAWRENCEVILLE, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, invites investors to mark their calendars for its R&D Day event to be... Read More

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immuno-oncology therapy, today reported financial results for the three and six months ended June 30, 2024. The Company also provided an update on its clinical development programs with IMNN-001, including... Read More

LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc . (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Wednesday, August 14, 2024 to discuss financial results for the second quarter ended June 30, 2024 and provide an update on its clinical... Read More

L AWRENCEVILLE, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its common stock priced at-the-market under Nasdaq rules. In a concurrent private placement and also pursuant to the securities... Read More

Phase 2 OVATION 2 Study of IMNN-001 a dministered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in overall survival (OS) in the intent-to-treat patient population compared with the standard-of-care control arm OS was extended by 15.7 months in patients receiving three or more doses of IMNN-001 in the 17-dose protocol Patients also receiving maintenance PARP inhibitor therapy... Read More

Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, will issue a news release announcing topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer tomorrow,... Read More

Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in advanced development of its non-viral DNA-mediated immunotherapy, announces database lock for its Phase 2 OVATION 2 Study evaluating the safety and efficacy of IMNN-001 in patients with... Read More

DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform’s potential as a next-generation vaccine, announces that the first participants have been treated in the IMNN-101 Phase 1... Read More

LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin ® ) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at... Read More

Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage drug development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced that DM Clinical Research in Philadelphia... Read More

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the three months ended March 31, 2024. The Company also provided an update on its clinical development programs with... Read More

Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy... Read More

LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, May 13, 2024 to discuss financial results for the first quarter ended March 31, 2024 and provide an update on its clinical development... Read More

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter LAWRENCEVILLE, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces receipt of clearance from the U.S. Food and Drug Administration (FDA) to... Read More

LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance... Read More

Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with... Read More

Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, announces receipt of $1.3 million in net cash proceeds from the sale of approximately $1.4 million of its unused New Jersey... Read More

LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m. ET on Thursday, March 28, 2024 to discuss financial results for the year ended December 31, 2023 and provide an update on its clinical development... Read More

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2 The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA LAWRENCEVILLE, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc . (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces it has... Read More

Executive Chairman to lead day-to-day operations, active search underway for CEO successor. Timing of upcoming milestones for key programs remains unchanged. LAWRENCEVILLE, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc . (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Dr. Corinne Le Goff, Pharm.D. has... Read More

Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality LAWRENCEVILLE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces positive results from a live virus challenge study conducted... Read More

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase... Read More

Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an article titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine... Read More

Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer,... Read More

Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON’s PlaCCine modality and its applicability to multiple pathogens LAWRENCEVILLE, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company focused on harnessing the power of the immune system against cancer and infectious diseases, announces that Jean Boyer, Ph.D., vice president of preclinical research... Read More

Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Conference Call Begins Today at 10:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immuno-oncology therapies and... Read More

LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m. ET on Tuesday, November 14, 2023 to discuss financial results for the third quarter and nine-months ended September 30, 2023 and provide an update on... Read More

Highlights advantages of IMUNON’s PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company focused on harnessing the power of the immune system against cancer and infectious diseases, announces that Khursheed Anwer, Ph.D., IMUNON’s executive vice president and chief science officer, will highlight the... Read More

“ A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics” presented by the Foreign Policy Association LAWRENCEVILLE, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company focused on harnessing the power of the immune system against cancer and infectious diseases, announces that Dr. Corinne Le Goff, IMUNON’s President and Chief Executive Officer, will be... Read More

The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that the first patient in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with... Read More

Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas ™ and Indiplas ™ modalities in immuno-oncology. LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the... Read More

Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS and OS trend compared with control arm Continued follow-up is indicated to confirm initial observations LAWRENCEVILLE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapies... Read More

Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced the release of an enterprise video that highlights the company’s mission,... Read More

Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&D Day event tomorrow, September 14 th beginning at 4:00 p.m. Eastern time.... Read More

Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that it will hold a virtual R&D Day event on September 14 th beginning at 4:00... Read More

LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25 th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the IMUNON presentation will be available on the Events section of the Company’s website beginning Monday, September 11 at 7:00 a.m. Eastern time.... Read More

CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidate s in animal models LAWRENCEVILLE, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the... Read More

Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the addition of Sachet A. Shukla, Ph.D. to the company’s scientific advisory board (SAB).... Read More

Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immuno-oncology therapies and next-generation... Read More

LAWRENCEVILLE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that a manuscript titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer,” is available on the preprint server bioRxiv [ here ].... Read More

LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, August 10, 2023 to discuss financial results for the second quarter and six-months ended June 30, 2023 and provide an update on its... Read More

Production of cGMP Clinical Materials Supports R&D Efficiencies and Lowers Costs for Infectious Disease and Cancer Vaccines, and Non-viral DNA-based Immuno-Oncology Therapies HUNTSVILLE, Ala., June 27, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, today unveiled its new current Good Manufacturing Practices (cGMP) clinical materials production facility, located on the Huntsville... Read More

LAWRENCEVILLE, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN ), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 5,000 shares of common stock and (ii)... Read More

Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of ovarian cancer during a panel discussion LAWRENCEVILLE, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc . (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Dr. Corinne Le Goff, President and Chief Executive Officer,... Read More

Dr. Corinne Le Goff highlights clinical progress across the Company’s pipeline , p rovides context on the promise of DNA as a therapeutic and a vaccine LAWRENCEVILLE, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that President and Chief Executive Officer Dr.... Read More

New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., the company’s Executive Vice President and Chief Science... Read More

Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced... Read More

LAWRENCEVILLE, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. EDT on Thursday, May 11, 2023 to discuss financial results for the first quarter ended March 31, 2023 and provide an update on its clinical development... Read More

Findings from a m ouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical studies LAWRENCEVILLE, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that a poster highlighting the Company’s DNA-based... Read More

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the year ended December 31, 2022, and provided an update on its clinical development programs with IMNN-001 (formerly GEN-1),... Read More

LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 30, 2023 to discuss financial results for the fourth quarter and full year ended December 31, 2022 and provide an update on its... Read More

Chief Science Officer describes compelling preclinical data supporting continued development of PLACCINE as a differentiated, next-generation vaccine modality LAWRENCEVILLE, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., Executive Vice... Read More

LAWRENCEVILLE, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN ), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 5,250 shares of common stock and (ii)... Read More

LAWRENCEVILLE, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- I MUNON , Inc. (NASDAQ: IMNN ) , a clinical-stage drug development company, today announced that an abstract related to the Company’s DNA-based immunotherapy has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19 at the Orange County Convention Center in Orlando, FL and virtually. The... Read More

Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company, today announced that Dr. Corinne Le Goff, the company’s president and chief executive officer, has issued the following letter to shareholders. To Our Shareholders: Several transformative events during 2022 laid the... Read More

The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ and CAMBRIDGE, MA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ) , a clinical-stage biotechnology company, and Break Through Cancer, a public foundation dedicated to empowering outstanding researchers and clinicians to both intercept and find cures for some of the most... Read More

Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025 The sale of an additional $1.8 million of unused New Jersey NOLs expected in 2023 LAWRENCEVILLE, NJ, Jan. 12, 2023 (GLOBE NEWSWIRE) -- I MUNON , Inc. (NASDAQ: IMNN ) , a clinical-stage drug development company today announced it has received $1.6 million in net cash proceeds from the sale of approximately $1.7 million of its unused... Read More

LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN ) , a clinical-stage drug development company, and The Wistar Institute , a global leader in biomedical research located in the heart of University City, Philadelphia, through its Vaccine & Immunotherapy Center, announce the signing of a first collaborative research agreement to research and develop new vaccine formulations... Read More

LAWRENCEVILLE, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- I MUNON , Inc. (NASDAQ: IMNN ), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 19,000 shares of common stock and (ii)... Read More

Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform IMUNON’s Executive Chairman to join Transomic’s Board of Directors LAWRENCEVILLE, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced a $375,000 investment in... Read More

CEO of Curis brings extensive biopharmaceutical financial experience to the Board Imunon , Inc. (N asdaq : IMNN ) , a clinical-stage drug development company, announces the appointment of James E. Dentzer to its Board of Directors, effective immediately. Mr. Dentzer is the chief executive officer of Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, and... Read More

Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines Imunon , Inc. (NASDAQ: IMNN ) , a clinical-stage drug development company, reports that partial results from an ongoing non-human primate study designed to examine the immunogenicity of its proprietary PLACCINE vaccine support PLACCINE as a viable alternative to mRNA vaccines. The study examined a single plasmid DNA vector containing the SARS-CoV-2 Alpha... Read More

Imunon , Inc. (NASDAQ: IMNN ), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 8,500 shares of common stock and (ii) restricted stock grants (the "Inducement Stock Grants")... Read More

Imunon , Inc. (NASDAQ: IMNN ), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming Chardan 6 th Annual Genetic Medicines Conference. The conference will be held on October 3-4 with in-person participation held at the Westin Grand Central Hotel in New York City. Dr. Le Goff... Read More